Harrow ($HROW) Partners with Samsung Bioepis for U.S. Ophthalmology Biosimilar Launch

Harrow (HROW) has entered into a definitive agreement with Samsung Bioepis Co. Ltd. to secure exclusive U.S. commercial rights to Samsung Bioepis’s ophthalmology biosimilar portfolio.

This acquisition strengthens Harrow Health (HROW) as the leading full-spectrum ophthalmic pharmaceuticals provider in the U.S., expanding its pipeline with high-value biosimilars for sight-threatening retinal diseases.

The transition is expected to be finalized by the end of 2025 for Harrow (HROW).

Harrow Therapeutics’ acquisition of these products could significantly reduce costs for Medicare and commercial plans while enhancing access and affordability for patients.

Mark L. Baum, Chairman and CEO of Harrow (HROW), stated, “This transformational acquisition marks a pivotal moment for Harrow and reinforces our commitment to delivering innovation, accessibility, and value to the U.S. ophthalmology community.”

Exit mobile version